The present study reveals the possible mechanisms of sivelestat against oxidative stress-induced AKI, including decreasing the level of MDA and increasing the levels of SOD and GSH-Px, and shows the possible therapeutic potential of sivelestat for sepsis-related AKI. This evidence concerns the gene SOD1 and acute kidney injury.